Latest Health News

Australian Clinical Labs (ASX: ACL) delivered a modest 1.7% underlying EBIT increase in FY26, navigating subdued revenue and rising labour costs with operational efficiencies and strategic initiatives.

Novo Resources has progressed its Belltopper Gold Project with a planned diamond drilling campaign and completed maiden Pilbara drilling programs, while reporting a $3.9 million net loss for H1 2026 and bolstering liquidity through capital raises.

Marlin Global delivered a robust 3.1% gross portfolio return in July 2026, significantly outpacing its benchmark which fell 3.6%, thanks to strategic semiconductor underweighting and strong gains in tech giants Microsoft, Dexcom, and Amazon.

Thrive Tribe Technologies has completed a small-scale capital raise, issuing 235 million shares at $0.001 each to bolster working capital. The lead manager, Clee Capital, will receive a fee and options subject to shareholder approval.

ResMed Inc. posted a 10% rise in fiscal 2026 revenue to $5.65 billion, bolstered by the acquisition of Noctrix Health and an agreement to sell its MatrixCare business. The company continues to invest in AI-powered digital health solutions amid ongoing patent litigation and a shifting regulatory landscape.

Motio Limited delivered a robust FY26 with profit before tax rising to $1.622 million, underpinned by record revenue months and a strengthened balance sheet following a capital raise.

QBE Insurance Group posted a modest 1% increase in net profit to US$1.03 billion for the first half of 2026, underpinned by steady premium growth and disciplined underwriting.

Green Cross Health CEO Rachael Newfield will step down in January 2027 following the sale of the Medical division, paving the way for a new pharmacy-centric leadership role.

Mayfield Childcare's Mayfield 360 division has achieved registration as an NDIS provider, enabling it to expand early intervention support services and transition from pilot to billable operations.

The WCM Quality Global Growth Fund posted a -5.20% return in July 2026, underperforming its MSCI benchmark as semiconductor stocks faltered. Despite short-term setbacks, the fund maintains strong long-term outperformance and is increasing exposure to AI-related companies.

FINEOS Corporation Holdings PLC reported a robust half with 7.9% total revenue growth, a 32% jump in EBITDA, and a return to net profit driven by subscription sales and operational efficiencies.

Proteomics International has achieved a key patent acceptance in Australia for its PromarkerEndo blood test, reinforcing its intellectual property portfolio and commercialisation strategy in a major healthcare market.